Results 161 to 170 of about 21,457 (213)

How should immune checkpoint inhibitor myocarditis be treated? [PDF]

Cardiooncology
Badaan S, Abbass A, Tov S, Bar-Sela G, Bisharat N.   +4 more
europepmc   +1 more source

Association of Disease-Modifying Antirheumatic Drugs (DMARDs) with Cardiovascular Diseases: Evidence from a Drug Target Mendelian Randomization Study. [PDF]

Glob Heart
Zhuo C, Chen L, Sun X, Chen T, Cai H, Hu X.   +5 more
europepmc   +1 more source

Targeted Therapy for Idiopathic Inflammatory Myopathy. [PDF]

J Cachexia Sarcopenia Muscle
Wang R, Lin W, Xie Q, Yin G.
europepmc   +1 more source

Spontaneous Regression of a Retinal Mass With Epstein-Barr Virus-Positive and Cytomegalovirus-Positive Panuveitis in Methotrexate-Associated Lymphoproliferative Disorder. [PDF]

Cureus
Watanabe R, Koto T, Keino H.
europepmc   +1 more source

New age GVHD prophylaxis regimens: what works for what donor and why. [PDF]

Hematology Am Soc Hematol Educ Program
Gooptu M, Koreth J.
europepmc   +1 more source

Non-TNF-targeted drugs in rheumatic diseasescombined with latent tuberculosis infection. [PDF]

Clin Exp Med
Xiang Z, Liuyu, Zou H.
europepmc   +1 more source

Infections requiring hospitalization in the abatacept clinical development program: an epidemiological assessment [PDF]

Allison Covucci, Diane Lacaille, Frederick Wolfe, Jarrod Franklin, Johan Askling, Marc C Hochberg, null null, Samy Suissa, Teresa A Simon   +8 more
core   +1 more source

The immune landscape of systemic sclerosis: from pathogenic mechanisms to precision therapeutic breakthroughs. [PDF]

Front Immunol
Liu M.
europepmc   +1 more source

Associations between 6-minute walk distance and physiologic measures and clinical outcomes in myositis-associated interstitial lung disease. [PDF]

Rheumatology (Oxford)
Bae SS, Markovic D, Saygin D, Sullivan D, Yamaguchi K, Moghadam-Kia S, Oddis CV, Abtin F, Kim GHJ, Marder G, Venuturupalli S, Dellaripa PF, Danoff S, Doyle T, Hunninghake G, Lee JS, Falk J, Johnson C, Goldin J, Tashkin D, Charles-Schoeman C, Aggarwal R.   +21 more
europepmc   +1 more source

Abatacept and the risk of malignancy: a meta-analysis across disease indications. [PDF]

Rheumatology (Oxford)
Zuckerman BP, Gibson M, Roy R, Hughes M, Mehta D, Yang Z, Adas M, Ng K, Russell MD, Cope A, Norton S, Galloway J.   +11 more
europepmc   +1 more source